Quick Answer
Aquestive Therapeutics, Inc. reported Cash and Equivalents of $31.81 million for fiscal year 2020.
Aquestive Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2020 | $31.81M | -35.5% |
| 2019 | $49.33M | -18.6% |
| 2018 | $60.60M | +248.7% |
| 2017 | $17.38M | +88.7% |
| 2016 | $9.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $129.06M | +65.7% | +113.2% |
| June 30, 2025 | $60.54M | -32.6% | -11.8% |
| March 31, 2025 | $68.66M | -27.9% | -4.0% |
| December 31, 2024 | $71.55M | +199.7% | -8.1% |
| September 30, 2024 | $77.89M | +212.6% | -13.3% |
| June 30, 2024 | $89.87M | +300.6% | -5.6% |
| March 31, 2024 | $95.20M | +254.1% | +298.8% |
| December 31, 2023 | $23.87M | -12.5% | -4.2% |
- Aquestive Therapeutics, Inc. showed a decrease of -35.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2020 period, Aquestive Therapeutics, Inc.’s cash and equivalents has grown by 245.4% (from $9.21 million to $31.81 million).
- The most recent figure is from Aquestive Therapeutics, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 9, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: